- Home
- EDUC vs MTVA Comparison
EDUC vs MTVA Comparison
Compare EDUC & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDUC
- MTVA
- Stock Information
- Founded
- EDUC 1965
- MTVA 2014
- Country
- EDUC United States
- MTVA United States
- Employees
- EDUC N/A
- MTVA N/A
- Industry
- EDUC Consumer Specialties
- MTVA
- Sector
- EDUC Consumer Discretionary
- MTVA
- Exchange
- EDUC Nasdaq
- MTVA NYSE
- Market Cap
- EDUC 14.6M
- MTVA 16.8M
- IPO Year
- EDUC N/A
- MTVA N/A
- Fundamental
- Price
- EDUC $1.54
- MTVA $1.60
- Analyst Decision
- EDUC
- MTVA Strong Buy
- Analyst Count
- EDUC 0
- MTVA 1
- Target Price
- EDUC N/A
- MTVA $12.00
- AVG Volume (30 Days)
- EDUC 9.2K
- MTVA 23.0K
- Earning Date
- EDUC 01-13-2025
- MTVA 03-27-2025
- Dividend Yield
- EDUC N/A
- MTVA N/A
- EPS Growth
- EDUC N/A
- MTVA N/A
- EPS
- EDUC N/A
- MTVA N/A
- Revenue
- EDUC $36,523,200.00
- MTVA N/A
- Revenue This Year
- EDUC N/A
- MTVA N/A
- Revenue Next Year
- EDUC N/A
- MTVA N/A
- P/E Ratio
- EDUC N/A
- MTVA N/A
- Revenue Growth
- EDUC N/A
- MTVA N/A
- 52 Week Low
- EDUC $1.46
- MTVA $1.51
- 52 Week High
- EDUC $2.95
- MTVA $6.75
- Technical
- Relative Strength Index (RSI)
- EDUC 41.93
- MTVA N/A
- Support Level
- EDUC $1.51
- MTVA N/A
- Resistance Level
- EDUC $1.67
- MTVA N/A
- Average True Range (ATR)
- EDUC 0.08
- MTVA 0.00
- MACD
- EDUC -0.00
- MTVA 0.00
- Stochastic Oscillator
- EDUC 21.05
- MTVA 0.00
About EDUC Educational Development Corporation
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.